Durable responses in SCLC with Tarlatamab by Jacob Sands et al. – ACS Journal Cancer
ACS Journal Cancer shared a post on X about a recent paper by Jacob Sands et al. published in Cancer Journal:
“In the phase 2 DeLLphi-301 trial, tarlatamab showed durable responses in SCLC, but adverse events management is critical.
How to manage? Read more.”
Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, shared this post, adding:
“Excited to get this guidance out for management of pateints on tarlatamab. CRS and ICANS manageable.
Check out guidance on dysguesia which is surprisingly effective. Appreciate all co-authors who provided valuable insights for this manuscript. It’s improved my management too!”
Authors: Jacob Sands, Stéphane Champiat, Horst-Dieter Hummel, Sujoy Mukherjee, Taofeek Owonikoko et al.
More posts featuring ACS Journal Cancer and Jacob Sands.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023